Ribociclib and Bicalutamide in AR+ TNBC
Ribociclib and Bicalutamide in AR+ TNBC
Active, not recruiting · NCT03090165 · Registry updated 2026-01-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ribociclib and Bicalutamide in AR+ TNBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-01-02 | NCT03090165 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Big Ten Cancer Research Consortium | 2 |
| Kari Wisinski | 2 |
| Novartis | 114 |
| University of Wisconsin, Madison | 265 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Michigan State University | Lansing | United States | 2 |
| Penn State Cancer Institute | Hershey | United States | 17 |
| Rutgers Cancer Institute of New Jersey | New Brunswick | United States | 223 |
| University of Illinois Cancer Center | Chicago | United States | 34 |
| University of Rochester Medical Center | Rochester | United States | 162 |
| University of Wisconsin | Madison | United States | 85 |